Compare PWP & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PWP | CRVS |
|---|---|---|
| Founded | 2006 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | 2016 |
| Metric | PWP | CRVS |
|---|---|---|
| Price | $13.28 | $9.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $21.63 | ★ $33.14 |
| AVG Volume (30 Days) | ★ 2.4M | 1.2M |
| Earning Date | 10-29-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ 138.52 | 48.04 |
| EPS | ★ 0.08 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.21 | N/A |
| Revenue Next Year | $24.08 | N/A |
| P/E Ratio | $165.38 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $12.52 | $6.39 |
| 52 Week High | $25.93 | $26.95 |
| Indicator | PWP | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 35.35 | 30.01 |
| Support Level | $12.52 | $6.39 |
| Resistance Level | $17.48 | $13.73 |
| Average True Range (ATR) | 1.01 | 0.59 |
| MACD | -0.20 | -0.06 |
| Stochastic Oscillator | 12.23 | 11.37 |
Perella Weinberg Partners is an independent advisory firm that provides strategic and financial advice to a wide range of clients. The Company's activities as an investment banking advisory firm constitute a single business segment that provides a range of advisory services, including advice related to strategic and financial decisions, mergers and acquisitions execution, shareholder and defense advisory, financing and capital solutions advice with resources focused on restructuring and liability management, capital markets advisory, private capital placement, as well as specialized underwriting and research services for the energy and related industries.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.